
NICE issues ‘final no’ to first AL amyloidosis treatment in England and Wales
The very first treatment for AL amyloidosis, DaraCyBorD, was rejected today by the National Institute for Health and Care Excellence (NICE).
The four-drug combination has been shown to be effective in clinical trials with patients five times more likely to have a complete response to treatment. However, NICE argued that there was insufficient data to show how much longer patients live for post-treatment and that it’s not cost-effective.
The news comes three months after the same treatment was approved and rolled out to newly-diagnosed patients in Scotland on the NHS.
This is a significant setback for patients in England and Wales, who currently have to rely on treatments designed for other conditions.
Huw Stiley, who served as a patient expert, championing the voice of the AL amyloidosis community at NICE’s appraisal committee told us:
“Any newly-diagnosed amyloidosis patient in England and Wales will be devastated to learn a treatment pathway available in Scotland has now been denied to them. The proposal issued to Scotland was broadly identical, one would assume, to the one issued to NICE. How can two different panels arrive at two completely different conclusions? If Scotland has approved DaraCyBorD, that implies the treatment delivers tangible clinical results and an improved quality of life for patients.”
Huw, who was diagnosed in 2016, added:
“It feels like there is a monetary dimension to the decision and I sincerely hope the drug company and NICE can find a way forward. Amyloidosis patients in England and Wales deserve a treatment pathway just like Scotland.”
We think this decision is unacceptable, and Myeloma UK will do everything we can to fight this decision, but we need your help.
Our CEO, Dr Sophie Castel said:
“This decision is a huge setback for the AL amyloidosis community and, quite frankly, utterly unacceptable. We know this new drug combination works and helps to improve people’s quality of life and remission times.
“Patients have told us time and time again how hopeless they feel knowing that they’ve been diagnosed with a condition which has no dedicated treatment option. To keep this game-changing treatment out of their reach is devastating. Particularly when fellow patients in Scotland have benefitted from DaraCyBorD on the NHS for months now.
“Access to vital treatments should not come down to a postcode lottery. We will appeal this decision and we’re calling on patients and their families to write to their MPs and join the fight for DaraCyBorD. We won’t rest until DaraCyBorD is available to every last patient who needs it, no matter where they live.”
Ways you can get help
Share your story
Sharing the impact that this decision has had on real people is one of the most powerful ways to make an impact with the press and decisions makers so please consider sharing your story with us.
Contact your MP
Write to your MP and ask them to raise this issue in parliament and to write to the Secretary of State for Health and Social Care, Steve Barclay and to the Chief Executive of NICE.
We’ve drafted a template letter to help you which has the basic information, but it’s more powerful if you add in your own story. You don’t have to have AL amyloidosis to support the campaign.
TheyWorkForYou.com is a useful site to help you find out who your MP is.
Most MPs are on social media so you can also contact them there and ask them to support our campaign or you could request to meet with your MP to talk about the issue.
If you have any questions or need support with any of this then please contact our Head of Campaigns, Janis McCulloch by emailing comms@myeloma.org.uk. We’d also love to know if you do contact your MP and what their response is.
We know that this decision will be upsetting for many people. If you need any support, please don’t hesitate to call the Myeloma Infoline on 0800 980 3332 (UK) or 1800 937 773 (Ireland) or email us at askthenurse@myeloma.org.uk
Browse other news categories

Stay in touch
We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.







